Advertisements

Omeprazole Actavis

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Omeprazole Actavis

Property Description
Active ingredient Omeprazole
Form Modified Release Capsule (Oral Dosage Form)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of gastric acid secretion
Origin Synthetic, substituted benzimidazole derivative

Omeprazole Actavis: Defining the Antisecretory Class

Omeprazole Actavis is a specific pharmaceutical preparation containing the active ingredient, omeprazole. This medication is classified as a proton pump inhibitor (PPI), which belongs to the therapeutic group of antisecretory compounds. The substance omeprazole is a synthetic compound derived from the substituted benzimidazole group. The classification as a PPI is key, as this group is clinically recognized for achieving potent, sustained control over gastric acid levels.

Composition and Delivery Form

The core component of the drug is omeprazole, contained within a modified release capsule for oral dosage. This particular pharmaceutical form is used because omeprazole is inherently unstable in highly acidic conditions. To protect the compound, the capsule utilizes specialized enteric-coated granules. This engineering allows the drug to bypass the stomach and dissolve upon reaching the small intestine for absorption. The structural design is intended to facilitate the effective delivery of the acid-labile substance.

General Purpose: Controlling Excessive Gastric Acid

The general purpose of Omeprazole Actavis is to achieve powerful and sustained suppression of gastric acid secretion. This is accomplished by the drug selectively targeting and inhibiting the proton pump system—the final step in the stomach's acid production pathway. This mechanism is crucial for allowing relief in scenarios where acid production is excessive or causing irritation. Proton pump inhibitors act to block the acid pump, which minimizes the overall quantity of acid the stomach produces throughout the day.

Regulatory References

  1. Proton pump inhibitors (PPIs) - MedlinePlus
Advertisements

What side effects are possible with Omeprazole Actavis?

Possible Side Effects and Safety Information

The official safety profile for omeprazole is categorized by frequency and the body system affected, reflecting data documented in government regulatory sources. These classifications help structure the understanding of the medicine's potential risks without providing individual clinical advice.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are listed as Common in regulatory documentation, affecting the gastrointestinal and nervous systems. These may include headache, abdominal pain, nausea, diarrhea, and flatulence. Reactions classified as Uncommon include dizziness, rash, and increased liver enzyme levels. Adverse reactions designated as Rare or Very Rare encompass more serious or infrequent events, such as certain blood disorders, severe hypersensitivity reactions, and severe skin conditions.

Serious and Long-Term Safety Considerations

The medicine's regulatory label documents specific serious adverse reactions. These include Acute Tubulointerstitial Nephritis (TIN), which is an inflammation of the kidney, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome. Additionally, an increased risk of specific bone fractures (hip, wrist, or spine) is associated with long-term, daily use. Other effects noted with prolonged exposure include Hypomagnesemia (low blood magnesium levels) and the formation of Fundic Gland Polyps.

Population-Specific Safety Notes

The safety profile in pediatric patients is generally similar to that observed in adults, though certain events like fever were reported more frequently in studies. For patients with hepatic impairment, the official safety notes indicate that the body's metabolism of the medicine may be impaired, which can result in increased systemic exposure. The label also contains a general constraint that a patient's symptomatic response to therapy does not exclude the possible presence of gastric malignancy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented descriptions of omeprazole overdosage and the mandatory regulatory guidance on seeking medical attention.

Overdosage with omeprazole, even in exposures up to 2,400 mg, is generally described in regulatory labeling as resulting in manifestations that are transient and non-serious. No specific severe or life-threatening clinical outcomes have been consistently reported in official documentation.


Documented Clinical Manifestations

Official regulatory sources document that overdose may present with symptoms affecting several systems, including:

  • Gastrointestinal: Nausea, vomiting, diarrhea, and abdominal pain.
  • CNS/Systemic: Headache, confusion, blurred vision, flushing, and increased sweating.

Regulatory Actions and Management

Management Aspect Official Regulatory Statement
Immediate Action Required Get medical help or contact a Poison Control Center right away for any suspected overdosage.
Urgent Medical Services Immediate contact with emergency services (e.g., 911) is required if the person experiences severe, life-threatening symptoms such as collapse, seizure, or trouble breathing.
Antidote Status No specific antidote is known for omeprazole overdosage.
Treatment Focus Management is strictly required to be symptomatic and supportive, addressing the clinical signs as they manifest.

Procedures intended to substantially increase drug elimination, such as hemodialysis, are noted in regulatory information as being ineffective due to the drug’s extensive protein binding.

Advertisements

Therapeutic Uses of Omeprazole Actavis

Omeprazole Actavis is applied in addressing a range of conditions marked by excessive stomach acid production. It is commonly used to help with symptoms related to systemic imbalance and inflammatory or irritative states, which may assist with maintaining functional stability in contexts involving heightened systemic burden.

The medicine is indicated for managing conditions associated with acute or episodic changes in acid balance. This includes duodenal and gastric ulcers, reflux oesophagitis, symptomatic gastro-oesophageal reflux disease (GORD), and pathological hypersecretory conditions such as Zollinger-Ellison syndrome. It is also considered relevant for the eradication of Helicobacter pylori bacteria in peptic ulcer disease.

The medicine generally contributes to easing the overall symptom load related to physical discomfort. “It assists with maintaining a sense of stability when symptoms are more noticeable,” offering symptomatic relief that may help patients cope more steadily with symptom fluctuations, and supports general well-being during symptomatic phases.


Quick Fact: Supports Relief from Heartburn Omeprazole Actavis is relevant for easing symptoms that interfere with daily comfort, such as heartburn and acid regurgitation.

Regulatory References

  1. New Zealand Medsafe Data Sheet on Omeprazole Actavis
Advertisements

Eligibility and Restrictions for Use

Omeprazole Actavis eligibility is strictly governed by official regulatory criteria, establishing both absolute prohibitions and conditional use requirements.

Contraindicated Populations

Use is absolutely prohibited for patients with a known hypersensitivity to omeprazole, its drug class (substituted benzimidazoles), or any component of the formulation. It is also contraindicated in patients receiving specific antiretroviral medications, such as nelfinavir or rilpivirine, due to adverse drug-drug interactions. Patients with certain hereditary metabolic disorders, like sucrase-isomaltase insufficiency, must also not use this medicine due to excipients.

Age-Group and Condition Restrictions

The medicine is approved for Adults for all labeled uses. In pediatric patients, use is established for treating Erosive Esophagitis (EE) in infants as young as one month old and for symptomatic GERD in children aged one year and older. Use is generally not established or not recommended in infants under one month of age for any indication.

Patients with severe hepatic impairment (liver disease) should have a dosage adjustment considered due to altered drug elimination. Combination therapy with clarithromycin is also contraindicated in patients with liver impairment. During pregnancy and lactation, use is reserved for when the potential benefit outweighs the potential risk.

Advertisements

What should I know about interactions with other medicines?

Omeprazole Actavis’s official interaction profile is defined by its influence on metabolic enzymes and its modification of gastric acidity. This information is derived strictly from government regulatory documents.

Contraindicated Combinations and Restrictions Co-administration with the antiretroviral medicines Nelfinavir and Rilpivirine is contraindicated. This mandatory restriction is due to omeprazole significantly reducing the plasma concentrations of these substances, which risks a loss of their therapeutic effect. Furthermore, co-administration with the strong enzyme inducers Rifampin or the herbal product St. John's Wort should be avoided, as these are documented to reduce the omeprazole plasma concentration.

Interactions Affecting Plasma Exposure As an inhibitor of the CYP2C19 enzyme, omeprazole can prolong the systemic exposure and elimination of co-administered CYP2C19 substrates, including Diazepam, Phenytoin, and Warfarin. This enzyme inhibition also affects Clopidogrel, where co-administration diminishes its anti-platelet activity. Omeprazole increases the systemic exposure of Digoxin and Cilostazol and may elevate the serum concentrations of Methotrexate.

pH-Dependent Effects and Population Notes Omeprazole-induced suppression of gastric acid is a pharmacodynamic effect that reduces the absorption and bioavailability of medicines requiring an acidic environment, such as the antifungals Ketoconazole and Itraconazole. Conversely, individuals identified as CYP2C19 Poor Metabolizers are documented to experience greater systemic exposure to omeprazole itself.

Advertisements

Mechanism of Action

Omeprazole Actavis acts as an irreversible inhibitor, selectively targeting the H^+/ K^+-ATPase enzyme—the final common pathway for acid production in the stomach's parietal cells. The drug is an inactive prodrug that requires activation by concentrating and transforming into its active form, a sulfenamide, only within the highly acidic environment of the secretory canaliculi.


Irreversible Blockade of the Acid Pump

The active sulfenamide intermediate forms a permanent covalent bond with the proton pump, leading to irreversible enzyme blockade. By targeting this terminal step, the mechanism blocks the extrusion of hydrogen ions ( H^+) into the stomach lumen, independent of upstream secretagogue signals (like gastrin or histamine).


Prolonged Effect via Enzyme Turnover

The duration of the physiological effect is determined by the rate at which the parietal cells can synthesize and insert new, unblocked H^+/K^+-ATPase units into the membrane (a process taking approximately 18 to 24 hours). This biological constraint governs why the resulting physiological change—a suppression of gastric acidity leading to an elevation of intragastric pH—persists long after omeprazole has been cleared from the bloodstream.

Advertisements

Dosage and Administration Information

Administration Guidelines for Omeprazole Actavis

Omeprazole Actavis is administered orally in the form of a Delayed-Release Capsule. The capsule must be swallowed whole with water to ensure the integrity of the enteric-coated pellets. This coating is necessary to protect the active ingredient from stomach acid and facilitate its absorption later in the small intestine. The internal pellets must not be crushed or chewed. For patients unable to swallow the capsule, the pellets may be opened and mixed with a slightly acidic fluid (such as applesauce or fruit juice) and swallowed immediately, but not stored for later use.

The medicine is typically taken once daily (QD), preferably in the morning, and can be administered with or without food. Higher total daily doses (above 80 mg), such as those used in hypersecretory conditions, are usually taken in divided doses. Standard regimens for healing conditions like ulcers usually last 4 to 8 weeks, while maintenance therapy may require long-term use.


Dosing and Special Population Rules

Use Context Standard Adult Dose Special Adjustment Guidance
Healing/Treatment 20 mg or 40 mg once daily. Hepatic impairment: 10 mg to 20 mg daily may be sufficient.
Maintenance 10 mg or 20 mg once daily. Renal Impairment / Older Adults: No dose adjustment is required.

In the event of a missed dose, the dose is typically taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is skipped, and the regular schedule resumed without doubling the intake.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence in Monotherapy

Research has evaluated the activity of Compound X in moderate to severe inflammatory conditions. These studies focused on understanding the basic response to the compound when administered alone.

  • Initial trials reported a change in key inflammatory biomarkers (e.g., IL-6, TNF-alpha) across 75% of participants.
  • Participants reported greater changes in subjective well-being compared to those in the placebo group.
  • Research evaluated the activity of Compound X when administered as a monotherapy.

Evidence in Combination Therapy

Research has examined whether the administration of Compound X in combination with standard anti-rheumatic drugs is associated with changes in joint swelling and stiffness.

  • Research objectives included the evaluation of Compound X in combination with standard anti-rheumatic drugs.
  • A Phase 3 trial compared its outcomes to Treatment Y, reporting a 40% difference in ACR scores between Compound X and Treatment Y.

Special Populations and Safety Profile

The clinical development program evaluated the compound in specific patient groups.

  • Studies included patients with mild hepatic impairment to evaluate the pharmacokinetic profile in this subgroup.
  • One large-scale observational study explored whether co-administration with high-dose Vitamin C supplements affected outcomes.
  • The studies measured the incidence of serious adverse events, which was compared to the comparator group.
  • Research evaluated the outcomes associated with different dosages during the clinical development program.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omeprazole Actavis (FAQ)


Q: How long does it usually take for Omeprazole Actavis to start working?

According to official product information, the inhibitory effect on acid secretion begins within one hour of administration. However, maximum acid suppression is typically achieved after several days of consistent, once-daily dosing. The full therapeutic benefit may therefore become established after approximately four days of consistent use.


Q: Can taking Omeprazole Actavis for a long time cause any vitamin deficiency?

Official labeling notes that prolonged daily use of omeprazole may be associated with the development of Vitamin B12 deficiency (cyanocobalamin). This effect is generally related to the sustained acid suppression achieved by the medication.


Q: Why is Omeprazole Actavis sometimes prescribed for H. pylori?

Omeprazole is documented in official labeling for use in combination with specific antibiotics as part of a regimen to treat H. pylori infection, which is a common cause of peptic ulcers. The medication is used to suppress acid, which supports the environment needed for the antibiotics to work against the bacteria.


Q: Is Omeprazole Actavis used to treat conditions other than acid reflux?

Yes, official regulatory documents list several labeled conditions beyond general acid reflux symptoms. These include the healing and prevention of duodenal and stomach ulcers, use in combination therapy for H. pylori infection, and the long-term management of conditions involving excessive acid production, such as Zollinger-Ellison Syndrome.


Q: Why does Omeprazole Actavis carry a caution about Clostridium difficile (C. diff)?

Regulatory documents note that the use of omeprazole may be associated with an increased risk of severe diarrhea caused by an intestinal infection known as Clostridium difficile (often referred to as C. diff). This is a general caution related to the use of acid-suppressing agents.


Q: What is the Zollinger-Ellison Syndrome that Omeprazole Actavis is used to treat?

Zollinger-Ellison Syndrome is officially described as a rare condition in which the stomach produces excessively large amounts of acid due to a tumor. Omeprazole is used for the long-term treatment of this syndrome to control the hypersecretion of gastric acid.


Q: How does the time of day I take Omeprazole Actavis matter for its effectiveness?

The medicine is typically taken once daily, preferably in the morning. The medication's mechanism involves irreversibly blocking the acid pumps that are active at the time of administration, and administration in the morning is intended to optimize the suppression of acid secretion throughout the day.


Q: Can Omeprazole Actavis affect the absorption of iron?

Official information indicates that the acid suppression caused by omeprazole can reduce the absorption of medicines and substances that require an acidic stomach environment for proper uptake. Iron absorption may be reduced due to this pH-dependent effect.


Q: Why do some people say Omeprazole Actavis causes headaches?

Headache is classified in official safety documents as a common adverse reaction. This classification means it is one of the more frequently reported effects noted during clinical studies for the medication.


Q: Does Omeprazole Actavis affect my blood pressure?

Regulatory post-marketing reports include mentions of changes, such as elevated blood pressure (hypertension), which is reported as an adverse effect, but its frequency is not known.


Q: Does Omeprazole Actavis cause sleep issues or insomnia?

Insomnia is documented as an uncommon side effect in regulatory documents. Other documented Central Nervous System effects include general sleep disturbances and somnolence (drowsiness).


Q: Can Omeprazole Actavis be taken with antacids?

Antacids may be taken concurrently with Omeprazole Actavis for symptom relief. Regulatory documents do not list antacids as a contraindication or clinically significant interaction, especially since Omeprazole Actavis takes several days to achieve its maximum effect.


Q: What is the difference between Omeprazole Actavis capsules and tablets?

Omeprazole Actavis is officially supplied and described in regulatory documents as a Delayed-Release Capsule for oral administration. This capsule form contains specialized enteric-coated granules designed to protect the active ingredient from stomach acid.


Q: Does Omeprazole Actavis change the way my liver works?

Regulatory documents note that omeprazole metabolism occurs in the liver, and changes in function tests, such as increased liver enzyme levels, are reported as an uncommon adverse reaction. Dosage adjustments may be considered for patients with severe hepatic impairment.


Q: Does Omeprazole Actavis interact with any herbal supplements?

Official labeling advises against co-administration with the herbal product St. John's Wort, as this substance may cause a reduction in the concentration of omeprazole in the blood. This substance should be reviewed alongside other medications by a healthcare provider.


Q: Does Omeprazole Actavis cause hair loss in some users?

Regulatory safety documents list hair loss (alopecia) as an adverse reaction that occurs rarely in individuals taking the medication.


Q: Can Omeprazole Actavis interact with any common heart medications?

Yes, the drug is documented to interact with certain heart medications. This includes Digoxin (where omeprazole may increase its systemic exposure) and Clopidogrel (where omeprazole may diminish its anti-platelet activity).


Q: Does Omeprazole Actavis need a prescription or is it over-the-counter?

Omeprazole Actavis is discussed in official regulatory prescribing information as a prescription medicine. The active ingredient, omeprazole, is available in different strengths and preparations, some of which are available over-the-counter.


Q: Is Omeprazole Actavis a cure for GERD or just a treatment?

Official documents describe the drug's role in the treatment and maintenance of conditions like GERD and erosive esophagitis. It works by suppressing gastric acid secretion. No regulatory labeling describes the medicine as a cure for these chronic conditions.


Q: Can I drink alcohol while taking Omeprazole Actavis?

Regulatory documents do not list alcohol as a contraindication or an interaction that requires dose adjustment. However, consuming alcohol is known to stimulate acid production, which could potentially reduce the effectiveness of the medicine.


Q: How does Omeprazole Actavis interact with the birth control pill?

Official documents and supporting data indicate that omeprazole does not cause a clinically significant interaction that would reduce the effectiveness of standard hormonal birth control pills.


Q: Can Omeprazole Actavis cause weight gain?

While not classified as a common side effect, weight gain and rapid weight gain are documented in post-marketing surveillance reports as adverse effects of unknown incidence.


Q: Does Omeprazole Actavis affect the way thyroid medication works?

Omeprazole is documented to interact with thyroid medications such as levothyroxine. This interaction can result in decreased absorption of the thyroid medication due to reduced stomach acidity.


Q: Can Omeprazole Actavis make my skin more sensitive to the sun?

Official post-marketing reports include increased sensitivity of the skin to sunlight and the development of a rash that is noted to worsen with sun exposure. Protection from sun exposure is generally recommended when taking medication associated with this effect.


Q: What is the research status on Omeprazole Actavis and stomach cancer risk?

Observational studies have established an association between long-term use of PPIs like omeprazole and an increased risk of stomach cancer (gastric cancer). Regulatory documentation addresses the importance of balancing the benefits and risks when using the therapy long-term.


Advertisements

How should Omeprazole Actavis be stored and disposed of?

Omeprazole Actavis gastro-resistant capsules must be stored under specific regulatory conditions to protect the acid-labile formulation.

Official Storage and Handling

Storage Requirement Condition
Temperature Limit Store not above 25 C (blister) or 30 C (bottle) [1, 2].
Container & Protection Must be kept in the original package and protected from moisture [1, 3]. Bottle containers must be kept tightly closed [4].
Child Safety Keep out of the sight and reach of children [3].

If the capsule is opened and the pellets are mixed with food or liquid, the resulting mixture must be swallowed immediately or within 30 minutes and not saved for later use [5].

Official Disposal Requirements

Any unused or expired product must be disposed of in accordance with local requirements [4]. The medication is not included on the list of drugs recommended for flushing [6]. General disposal guidance for non-flushable medicines is to secure the contents in household trash after mixing with an undesirable substance [6].


Note: This information is based solely on governmental regulatory labeling and documents the required conditions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omeprazole Actavis found in:

A-Z Index: